Today’s biologic drugs are providing breakthrough treatment options for many of the world’s most challenging diseases and chronic conditions.
As a supplier for the largest biopharmaceutical manufacturers in the world, Avantor® is a trusted partner that provides the products, services, solutions and expertise necessary to quickly and confidently move through research and production. From the bench, to the pilot plant and through all steps required in full commercial manufacturing, we enable our customers to reach the market with new treatments for patients, faster and safer.
We provide a unique combination of industry expertise with a broad portfolio of products and materials engineered and manufactured to satisfy the highest quality standards and regulatory requirements for your final product—whether it is a vaccine, monoclonal antibody, recombinant protein, cell therapy, gene therapy or small molecule treatment.
Focused on the success of your applications and processes
An industry-leading portfolio.
Serving your needs from discovery to commercial launch, our portfolio of industry-leading production chemicals, single-use solutions and sera are backed by our deep commitment to quality and innovation.
A commitment to quality.
Our quality systems are proven and have been audited by biopharma manufacturers and regulatory bodies worldwide. We emphasize quality in all of our processes, starting with raw material procurement and ranging to cGMP manufacturing at multiple scales, handling and distribution.
Streamlined, global delivery.
Our channel, VWR®, part of Avantor, provides an integrated purchasing experience that is optimized for the way you do business, with access to an even broader selection of products to use in upstream and downstream processes as well as final fill formulations.
In the production of monoclonal antibodies (mAbs), finding ways to remove bottlenecks and improve yields in downstream processing continues to be a key focus area for biopharma manufacturers.
COVID-19 has compressed bioprocessing timelines, leaving no room for uncertainty in the characterization of raw materials and contaminants.
Opportunities for advancements and challenges in manufacturing processes still remain as the biopharmaceutical industry sharpens its focus on gene therapy.
From a full range of cGMP production chemicals, excipients and chromatography resins to single-use assemblies, our products address the need to maintain quality, activity and stability throughout the entire mAbs scale-up and production.
Recombinant proteins are manufactured using microbial (E. coli) expression systems. Choose from our offering of cell culture supplements, chromatography resins and a broad range of excipients for recombinant protein manufacturing.
Primarily developed to target infectious diseases, new vaccine concepts are now focusing on immune-oncology applications. Animal sera and buffer components are among the products we offer that are used in vaccine manufacturing.
Cell therapies are offering new hope for patients in the fight against life-altering diseases like cancer. Our fill and finish excipients, cell culture media and sera can be tailor packaged for the new cell therapy needs, and are among the products we offer for this developing bioprocessing application.
Gene therapies offer the prospect of curative benefits to patients with genetic or acquired diseases. From fermentation media to culture plasma DNA vectors, as well as purification of CAR vectors used to engineer T-cells, our resources can help drive new cures.
Single-use products and systems enable greater flexibility and speed in biopharma manufacturing. Avantor is an open-architecture provider of innovative, single-use technology to support your bioprocessing workflows.
No matter how the drug or treatment is delivered, small molecule pharmaceutical manufacturers know they can formulate, manufacture and innovate with confidence using excipients and other products from Avantor.
Buffers play a significant role in biopharmaceutical manufacturing. Avantor can help reduce the cost and time of buffer preparation with novel, alternative buffer management strategies that can be applied as either a stand-alone solution or in combination to achieve workflow improvements, depending on the size of your operations and facility.
Trust our experts to help you reduce downstream turnaround times and optimize buffer and chromatography resin selection in biopharma mAbs manufacturing.